Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Accuracy and Compliance in a Phase I/II Trial Involving Preterm Neonates

Pharm-Olam was contracted to provide clinical research services on a Phase I/II pediatric Respiratory Distress Syndrome study involving neonates with a gestational age between 27 and 33 weeks. This first in-human study required a single intratracheal administration within 24 to 48 hours of birth.

Discover the challenges Pharm-Olam encountered and the solutions implemented in this pediatric study.